Understanding LucenceINSIGHT™ Multi-Cancer Screening
Cancer is often most treatable when detected early. LucenceINSIGHT™ uses the power of liquid biopsy for cancer detection, a groundbreaking approach that analyzes circulating tumor DNA (ctDNA) in your blood. This ctDNA carries vital clues about cancer, even in its earliest stages, allowing for detection before symptoms appear.
Instead of invasive tissue biopsies, LucenceINSIGHT™ requires only a simple blood test to detect cancer early, making it a convenient and comfortable screening option.
Why Screen for Cancer Early?
- 5-year survival rates are significantly higher when cancer is detected and treated early.
- 4 out of 5 cancer deaths are from cancers not covered by routine screenings (breast, colorectal, cervical). 3-4
- Many common and deadly cancers (lung, pancreatic, liver) lack effective screening methods. Early detection efforts are crucial for these cancers.
- Breast, lung, bronchus, prostate, and colorectal cancers account for almost 50% of all new cancer cases in the United States, responsible for nearly 50% of all deaths. 2
- Cancer deaths in the United States are the leading cause of death for those under 65 years of age. 2
How is LucenceINSIGHT™ Different from Traditional Cancer Marker Tests?
Traditional cancer marker tests, such as CEA, CA19-9, and CA-125, measure specific proteins in the blood but have notable limitations. These tests exhibit low sensitivity and specificity, leading to false positives. Early-stage cancers may also be undetectable, resulting in false negatives.
Additionally, these markers are mainly used to monitor diagnosed cancers or check the recurrence of specific cancer types, limiting their use for broad multi-cancer screening and early detection in asymptomatic individuals.
LucenceINSIGHT™ directly analyzes ctDNA, the genetic material shed by cancer cells. This approach offers several advantages:
- Enhanced Detection: ctDNA testing is more sensitive and specific than traditional markers, allowing for high accuracy and earlier detection of cancer-related DNA.
- Comprehensive Screening: LucenceINSIGHT™ offers multi-cancer screenings, increasing the likelihood of identifying potential malignancies.
- Early Detection Potential: ctDNA can be found in blood before symptoms emerge, enabling earlier cancer detection and improving treatment success.
- Noninvasive Nature: LucenceINSIGHT™ requires only a simple blood draw, making cancer screening comfortable and convenient without biopsies.
Evidence Supporting LucenceINSIGHT™
Recent studies have demonstrated the effectiveness of LucenceINSIGHT™ in real-world settings. A 2023 study of 264 asymptomatic individuals found a 100% positive predictive value (PPV), meaning a positive result reliably indicates the presence of cancer.
Additionally, a 2024 study with 601 patient samples showed LucenceINSIGHT™ has 81% sensitivity and 99% specificity, demonstrating its effectiveness in correctly identifying cancer while reducing false positives.
What Cancers Can LucenceINSIGHT™ Screen For?
LucenceINSIGHT™ is designed to detect 12 cancer types, including some of the most common and aggressive types.
Is LucenceINSIGHT™ Right for You?
LucenceINSIGHT™ is intended for cancer screening in asymptomatic patients who prioritize proactive health management and want to be empowered with knowledge about their cancer risk. You might be a candidate if you:
- Have a family history of cancer
- Are concerned about your general cancer risk
- Seek a comprehensive and convenient cancer screening solution
- Are proactive about your health and well-being
Disclaimer: LucenceINSIGHT™ is a screening test, not a diagnostic testing substitute. It does not predict inherited cancer risk. Consult your doctor to discuss your risk factors and determine if LucenceINSIGHT™ suits you.
The LucenceINSIGHT™ Process: Simple, Streamlined, and Secure
Getting screened with LucenceINSIGHT™ is straightforward and hassle-free:
- Join Mito Health: Sign up and complete our health and lifestyle questionnaire. Then, book a LucenceInsight™ test directly on your Mito dashboard.
- Choose your Blood Draw Location: You can choose from one of more than 2,000 LabCorp locations in the United States or BioReference labs in New York, New Jersey, or Rhode Island.
- Blood Draw: A simple blood draw is performed at our convenient location. The procedure is quick, minimally invasive, and requires no special preparation.
- Comprehensive Report: In 12 to 18 working days, you'll receive a detailed, easy-to-understand report outlining your results.
- Results Discussion: Our team of top doctors will review your report with you, explain the findings, and recommend any necessary next steps.
Why Choose Mito Health for Your LucenceINSIGHT™ Test?
At Mito Health, we offer comprehensive lab tests, including LucenceINSIGHT™, to help you get the most in-depth picture of your health. Our top doctors create a personalized health action plan with tailored recommendations based on your test results.
